Date: 2015-01-26
Type of information: Company acquisition
Acquired company: SEPS Pharma (Belgium)
Acquiring company: Amatsi group (France)
Amount: undisclosed
Terms: * On January 26, 2015, Amatsi Group, a leading French supplier of services devoted to the development of both human and veterinary pharmaceutical products, announces the acquisition of Belgian company SEPS Pharma, which provides drug product development services, encompassing preformulation and formulation development, analytical drug product development, process development and clinical trial manufacturing. Within the framework of its international development and the expansion of its service offer aimed at the pharmaceutical industry, Amatsi Group will thus extend its services relating to the development of drugs for its clients, biotechs, Mid-size or Big Pharmas, to SEPS Pharma’s Belgian site. Thanks to this acquisition, AmatsiGroup intends to continue its growth and is targeting annual revenue of €33 million in 2015, versus €26 million in 2014 and €23 million in 2013.
Details: Founded in 2007 and located in Ghent, Belgium, SEPS Pharma counts a team of 30 highly-qualified people specialized in the development of innovative oral (liquid and solid dosage forms), inhalable and injectable formulations with acknowledged expertise in enhancing the bioavailability and controlling the drug release. With over 25 clients in Europe, US and Japan, the Belgian company recorded a 2014 revenue of €5 million. Amatsi Group provides international services covering four complementary strategic activities: Bioservices [in-life studies (PK, ADME, residue, tolerance) and preclinical and clinical bioanalysis], Pharmaceutical analysis solutions [analytical method development and validation, stability studies, quality control of raw materials and finished products], Formulation development and manufacturing [formulation development and production of sterile and non-sterile pilot and clinical batches], Clinical trial material logistics[GMP storage, packaging, labeling, QP release services and international distribution]. Amatsi Group, founded in 2010, was formed by the integration of four companies(Avogadro, Amatsi, DBI and Avepharm) bringing complementary expertise. The company has recently expanded its US operations and acquired an operation site in the US in Terre Haute (Indiana).
Related:
